Exit Sequencing

Exit Sequencing is the act of scheduling Cost Reduction programs, Revenue initiatives, and operational improvements against a known exit date to maximize Enterprise Value at the point of sale.

The core problem is temporal. Every program you run has three properties:

1. 1)Implementation Cost - what you spend to execute it
2. 2)EBITDA impact - how much it adds (or saves) annually once live
3. 3)Payback Period - how long before the program's cumulative EBITDA lift exceeds its cost

A Buyer values the business as a multiple of Enterprise Value to EBITDA. If your recent annual EBITDA is $12M and comparable businesses trade at 10x, your Enterprise Value is roughly $120M. Every $1M of incremental EBITDA you land before the Buyer's M&A due diligence period is worth $10M in Enterprise Value.

But programs that are half-finished at exit are worth less than doing nothing - and the reason is subtler than it first appears. A sophisticated Buyer will adjust the EBITDA they underwrite to exclude one-time Implementation Costs. So the cost itself is not the primary damage. The real damage is twofold. First, the Buyer will not credit projected EBITDA benefits from a program that has not yet proven it works. Unfinished means unproven, and unproven means zero in the Buyer's model. Second, a portfolio of half-complete initiatives signals Execution Risk. It tells the Buyer your management team over-committed and under-delivered, which reduces their confidence in the entire P&L - not just the unfinished program. The damage lands in the Buyer's risk assessment and their willingness to pay a premium multiple, not just in the accounting. So sequencing is not just about doing the best stuff first. It is about making sure everything you start has time to fully land and prove its impact before the Buyer evaluates the business.

If you have only ever built software, this is the concept that connects engineering Execution to the check your Equity Compensation gets written for.

As an Operator in a PE-Backed business, your P&L ownership directly determines exit proceeds. The sequence you choose has three compounding effects:

1. 1)EBITDA compounding - Programs that land early generate savings (or Revenue) that fund later programs. A $400K annual savings from vendor renegotiation in month 2 partially funds the $600K platform migration in month 6. This is investment sequencing applied to Operations.

2. 2)Narrative credibility - Buyers do not just underwrite current EBITDA. They underwrite trajectory. A P&L that shows 6 consecutive quarters of margin improvement tells a Turnaround story. A P&L that shows a sudden spike only in the final quarter signals desperation, not competence - the Buyer will discount it. The sequence is the story.

3. 3)Risk containment - Every program in flight is Execution Risk on the P&L. Running 5 programs simultaneously means 5 ways to miss your quarter. Exit Sequencing is also about controlling how much risk is live at any moment - your risk appetite should decrease as you approach the exit date, not increase.

Step 1: Build the Program Backlog

List every initiative that could improve EBITDA. For each, estimate:

• •Implementation Cost (one-time)
• •Annual EBITDA lift (steady-state)
• •Time to full impact (months)
• •Payback Period (Implementation Cost / monthly EBITDA lift)
• •Dependencies (does program B require program A to finish first?)

Step 2: Apply the Time Horizon Filter

Work backward from exit. If you have 18 months and a program takes 14 months to fully land, it must start in the first 4 months or not at all. Any program whose time to full impact exceeds the remaining runway is either cut or reduced in scope to capture partial benefit.

This is where Exit Criteria become operational - each program needs a clear definition of 'fully landed' so you can back-calculate whether it fits the window.

Step 3: Rank by ROI per Unit Time

Raw ROI is not enough. A program with 300% ROI over 3 years is worse than 80% ROI over 6 months if you are selling in 18 months. The ranking metric is:

Exit-Adjusted ROI = (Annual EBITDA lift x months of benefit before exit / 12) / Implementation Cost

This captures both the magnitude and the time the benefit is visible on the P&L before a Buyer sees it.

Month-counting convention used throughout this lesson: A program starting month S with T months of implementation begins generating EBITDA benefit at the start of month S + T. Months of visible benefit before an exit at the end of month E = E - S - T + 1. Example: a program starting month 1 with 3 months to land in an 18-month window produces benefit from month 4 through month 18 = 15 months.

Step 4: Sequence by Critical Path

Respect dependencies. If your pricing overhaul depends on customer segmentation data that comes from the platform migration, the migration has to go first regardless of its standalone ROI ranking.

Map the critical path. Then sequence: highest Exit-Adjusted ROI first, subject to dependency constraints and capacity limits.

Step 5: Build the Kill Line

Draw a horizontal line across your ranked list. Above the line: programs that fully land before exit. Below: programs you do not start. This is Capital Allocation under a deadline.

The kill line also applies during Execution. If a program is behind schedule at the halfway point, you need a decision rule: accelerate (spend more to compress the timeline), reduce scope (capture partial benefit), or kill (stop the bleeding and protect EBITDA).

Exit Sequencing applies whenever you are optimizing against a fixed Time Horizon with a known liquidity event:

• •PE exit prep - The classic case. Sponsor wants to sell in 12-24 months. Every operational decision is evaluated against exit value impact.
• •Annual planning in PE portfolio companies - Even without an imminent exit, smart PE operators sequence annual programs as if an exit could happen. This is capital discipline applied to Operations.
• •Turnaround Triage - When a business is burning cash and you need to sequence Cost Reduction programs to hit break-even before runway expires. The 'exit' here is solvency.

When NOT to use it: If you are in a growth-stage business with a long Investment Horizon and no exit pressure, rigid sequencing against an exit date can cause you to underinvest in programs with high long-term ROI but slow Payback Period. Exit Sequencing optimizes for near-term EBITDA, which can conflict with long-term Value Creation.

Exit Sequencing sits at the intersection of everything an Operator learns about P&L management. It uses ROI as the base ranking metric but transforms it with time - because a dollar of EBITDA lift that lands 12 months before exit is worth 6x more than one that lands 2 months before exit (6 additional months of visible benefit on the P&L the Buyer evaluates). It depends on EBITDA Optimization for the individual programs in the backlog - each program is itself an EBITDA Optimization initiative, and Exit Sequencing is the meta-problem of ordering them. It operationalizes Exit Criteria at two levels: each program needs its own Exit Criteria (how do we know vendor renegotiation is done?), and the overall exit has criteria the Buyer evaluates (is EBITDA stable? is the trajectory credible?). Downstream, this concept feeds directly into LBO Modeling - the Buyer's model of what they will pay is driven by the EBITDA you present, which is the output of your sequence. It also connects to Capital Allocation and NPV thinking: every program in your sequence is a Capital Investment, and the exit date functions as your Discount Factor anchor - benefits after exit accrue to the Buyer, not to you.